The UK Competition Authority decides to close its investigation into a pharmaceutical company's discount scheme, concluding that it is not likely to limit competition (Remicade)

Schulz, Axel P.; Abouzeid, Fanny; Lacerda, Joao

Previous article The EU Commission imposes a fine of € 1.49 billion on a search engine company for abusing its dominant position by imposing restrictive clauses in contracts with third-party websites (Google AdSense) Next article The Turkish Competition Authority launches an investigation into a search engine company for alleged abuse of dominance in the online search market (Google)

14 Mar 2019

The UK Competition Authority decides to close its investigation into a pharmaceutical company’s discount scheme, concluding that it is not likely to limit competition (Remicade)

KEYWORDS

Reference

UK Competition Authority, Remicade, Press Release, 14 March 2019

On 14 March 2019, the CMA decided to close its investigation into pharmaceutical company MSD's discount scheme for the medicine Remicade, concluding that it was not likely to limit competition. Previously, the CMA had issued a statement of objections,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Authors

Axel P. Schulz
White & Case (Brussels)

Germany 17 contributions 6773 visits
Fanny Abouzeid
White & Case (Brussels)

Belgium 5 contributions 1058 visits
Joao Lacerda
White & Case (Brussels)

Belgium 3 contributions 406 visits

Quotation

Axel P. Schulz, Fanny Abouzeid, Joao Lacerda, The UK Competition Authority decides to close its investigation into a pharmaceutical company’s discount scheme, concluding that it is not likely to limit competition (Remicade), 14 March 2019, e-Competitions March 2019, Art. N° 104692

Visites 48